CLS’ poster presented at 9th Annual Brain Mets Congress is now available on the company’s website

Clinical Laserthermia Systems AB (publ) participates in the 9th Annual Brain Metastases Research and Emerging Therapy Conference in Marseille, France, 4-5 October, and presents a poster titled “Laser thermal therapy for brain metastases: Ex vivo and in vivo validation in an ovine brain model”, demonstrating that the TRANBERG®|Thermal Therapy System is suited for highly precise and reliable ablation in brain tissue.

The poster is now available on the company’s website under https://clinicallaser.se/en/svenska-publikationer/posters/

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. 

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany and USA, is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser: Certified adviser (CA) isFNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se